Reactions 1704, p208 - 2 Jun 2018 Transaminitis: case report A 69-year-old man developed transaminitis during treatment with ipilimumab [route and dosage not stated]. The man, who had a V600E BRAF-mutated metastatic melanoma, started receiving treatment with trametinib, ipilimumab and dabrafenib. Despite the treatment, he had disease progression. He then received treatment with pembrolizumab and glembatumumab vedotin. In June 2016, he started receiving ipilimumab and nivolumab. However, he developed transaminitis, which was attributed to ipilimumab. Thereafter, his therapy was continued with nivolumab without any complication [duration of treatment to reaction onset and outcome not stated]. Author comment: "At this time in June 2016, the patient was started on ipilimumab and nivolumab. After experiencing transaminitis, he was continued on nivolumab alone, which he tolerated well." Schwager Z, et al. Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy. JAAD Case Reports 4: 421-423, No. 5, Jun 2018. Available from: URL: http://doi.org/10.1016/j.jdcr.2017.10.019 - USA 803323583 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera